| Phase 113 trials |
|
Phase 1
|
NCT07523711 |
Apr → Nov 2026 expected |
obesity disorder |
Amgen |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07313761 |
Dec 2025 → Jun 2026 |
— |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07229157 |
Oct 2025 → Aug 2026 overdue |
obesity disorder |
Amgen |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07226778 |
Oct 2025 → May 2026 |
obesity disorder |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07160257 |
Aug 2025 → Nov 2026 expected |
type 2 diabetes mellitus |
Amgen |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07429032 |
Apr → Nov 2025 |
obesity disorder |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07428525 |
Mar 2025 → Feb 2026 |
— |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07429045 |
Mar → Nov 2025 |
morbid obesity |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07310563 |
Dec 2024 → May 2025 |
obesity disorder |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06976372 |
Aug → Dec 2024 |
obesity disorder |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06352892 |
Apr → Aug 2024 |
obesity disorder |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05056246 |
Sep 2021 → Apr 2022 |
— |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04478708 |
Aug 2020 → Nov 2022 |
obesity disorder |
Amgen |
Completed
|
No outcome recorded
|
|
| Phase 23 trials |
|
Phase 2
|
NCT07441252 |
Mar 2026 → Sep 2027 expected |
NAFLD1 |
Amgen |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06660173 |
Nov 2024 → Oct 2025 overdue |
type 2 diabetes mellitus |
Amgen |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05669599 |
Jan 2023 → Oct 2024 |
obesity disorder, type 2 diabetes mellitus |
Amgen |
Completed
|
No outcome recorded
|
| Phase 310 trials |
|
Phase 3
|
NCT07684144 |
Jul 2026 → Dec 2027 expected |
obesity disorder, type 2 diabetes mellitus |
Amgen |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07684235 |
Jul 2026 → Dec 2027 expected |
obesity disorder |
Amgen |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07575399 |
May 2026 → Jan 2028 expected |
obesity disorder |
Amgen |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07225686 |
Dec 2025 → Sep 2027 expected |
obesity disorder, obstructive sleep apnea syndrome |
Amgen |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07226765 |
Nov 2025 → Sep 2027 expected |
obstructive sleep apnea syndrome |
Amgen |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07037433 |
Jul 2025 → Jun 2028 expected |
atherosclerotic cardiovascular disease, obesity disorder |
Amgen |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07037459 |
Jun 2025 → Jun 2028 expected |
diastolic heart failure, mild heart failure, obesity disorder |
Amgen |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06987695 |
Jun 2025 → Apr 2027 expected |
obesity disorder |
Amgen |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06858878 |
Mar 2025 → Jan 2027 expected |
type 2 diabetes mellitus |
Amgen |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06858839 |
Mar 2025 → Jan 2027 expected |
obesity disorder |
Amgen |
Active not recruiting
|
No outcome recorded
|